These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12474570)

  • 21. A comparison of memory performance in relapsing-remitting, primary progressive and secondary progressive, multiple sclerosis.
    Gaudino EA; Chiaravalloti ND; DeLuca J; Diamond BJ
    Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):32-44. PubMed ID: 11234907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence of cognitive compensation associated with educational level in early relapsing-remitting multiple sclerosis.
    Bonnet MC; Deloire MS; Salort E; Dousset V; Petry KG; Brochet B;
    J Neurol Sci; 2006 Dec; 251(1-2):23-8. PubMed ID: 17097108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive impairment in three subtypes of multiple sclerosis.
    Denney DR; Sworowski LA; Lynch SG
    Arch Clin Neuropsychol; 2005 Dec; 20(8):967-81. PubMed ID: 15961271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
    Hoogervorst EL; Polman CH; Barkhof F
    Mult Scler; 2002 Oct; 8(5):415-9. PubMed ID: 12356209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis.
    Moreira MA; Tilbery CP; Monteiro LP; Teixeira MM; Teixeira AL
    Acta Neurol Scand; 2006 Aug; 114(2):109-13. PubMed ID: 16867033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis.
    Dineen RA; Vilisaar J; Hlinka J; Bradshaw CM; Morgan PS; Constantinescu CS; Auer DP
    Brain; 2009 Jan; 132(Pt 1):239-49. PubMed ID: 18953055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study.
    Bergendal G; Fredrikson S; Almkvist O
    Eur Neurol; 2007; 57(4):193-202. PubMed ID: 17272938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Social cognition and Theory of Mind in patients with relapsing-remitting multiple sclerosis.
    Banati M; Sandor J; Mike A; Illes E; Bors L; Feldmann A; Herold R; Illes Z
    Eur J Neurol; 2010 Mar; 17(3):426-33. PubMed ID: 19922457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of high-dose intravenous methyl-prednisolone treatment on intraocular pressure in multiple sclerosis patients with relapse.
    Acar M; Gedizlioglu M; Koskderelioglu A; Ozturk F; Kilinc S; Talay N
    Eur Neurol; 2012; 68(1):20-2. PubMed ID: 22677889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone.
    Szczuciński A; Kalinowska A; Losy J
    Eur Neurol; 2007; 58(4):228-32. PubMed ID: 17827967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Change of interleukin-4 and interleukin-12 levels after therapy of multiple sclerosis relapse with methylprednisolone].
    Bartosik-Psujek H; Magryś A; Montewka-Kozioł M; Stelmasiak Z
    Neurol Neurochir Pol; 2005; 39(3):207-12. PubMed ID: 15981158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis.
    Bellmann-Strobl J; Wuerfel J; Aktas O; Dörr J; Wernecke KD; Zipp F; Paul F
    Neurology; 2009 Nov; 73(20):1624-7. PubMed ID: 19917984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.
    Martinelli V; Rocca MA; Annovazzi P; Pulizzi A; Rodegher M; Martinelli Boneschi F; Scotti R; Falini A; Sormani MP; Comi G; Filippi M
    Neurology; 2009 Dec; 73(22):1842-8. PubMed ID: 19949030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A longitudinal study of the evolution of cognitive function and affective state in patients with amyotrophic lateral sclerosis.
    Kilani M; Micallef J; Soubrouillard C; Rey-Lardiller D; Dematteï C; Dib M; Philippot P; Ceccaldi M; Pouget J; Blin O
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Mar; 5(1):46-54. PubMed ID: 15204024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Specificity of attention and cognitive inhibition processes in relapsing -remitting multiple sclerosis patients with consideration of their mood level].
    Tyburski E; Potemkowski A; Cheć M; Sołtys A; Mak M; Samochowiec A
    Psychiatr Pol; 2014; 48(2):307-18. PubMed ID: 25016768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of immunomodulation on psycho-neuroimmunological functions in benign multiple sclerosis.
    Haase CG; Tinnefeld M; Faustmann PM
    Neuroimmunomodulation; 2004; 11(6):365-72. PubMed ID: 15467351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.